Roche wins speedy FDA re­view for Tecen­triq; South Ko­re­an au­thor­i­ties to look in­to Sam­sung Bi­o­Log­ics ac­count­ing prac­tices

→ Trail­ing be­hind im­munother­a­py of­fer­ings from Mer­ck $MRK and Bris­tol-My­ers Squibb $BMY, Roche $RHH­BY has been plot­ting to se­cure ap­proval of its Tecen­triq for dif­fi­cult …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER